会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Antimicrobial compounds
    • 抗菌化合物
    • US07385086B2
    • 2008-06-10
    • US10764451
    • 2004-01-27
    • Craig A. TownsendJames D. DickGary R. PasternackFrancis P. KuhajdaNicole M. Parrish
    • Craig A. TownsendJames D. DickGary R. PasternackFrancis P. KuhajdaNicole M. Parrish
    • C07C317/00C07C317/02C07C317/04C07C317/06C07C317/08
    • C40B40/04C07C311/06C07C317/44
    • This invention provides compounds and methods for treating, with said compound, a mycobacterial infection by administering to an animal a pharmaceutical composition containing a compound having the formula R—SOn-Z-CO—Y, where R is an alkyl groups having 6-20 carbon atoms, unsaturated hydrocarbon groups having 6-20 carbon atoms, or alkyl groups having 6-20 carbon atoms interrupted by at least one aromatic ring; Z is —CH2—, —CH2CH2—, —NH—NH—, —O—, ——NH—, —O—NH—, —CH2—NH—, —CH2—O—, —NH—O—, —NH—CH2—, —O—CH2—, and —CH═CH—; Y is —NH2, —O—CH2—C6H5, —CO—CO—O—CH3, and —O—CH3; and n is 1 or 2. It has been discovered that these compounds treat microbially-based infections caused by corynebacteria, nocardiae, rhodococcus, and mycobacteria. These compounds may be used to treat mycobacterial cells, such as Mycobacteria tuberculosis, drug resistant M. tuberculosis, M. avium intracellulare, M. leprae, M. paratuberculosis, and pathogenic Mycobacteria sp.
    • 本发明提供了通过向动物施用含有具有式R-SO n -Z-CO-Y的化合物的药物组合物,通过向所述化合物处理分枝杆菌感染的化合物和方法,其中R 是具有6-20个碳原子的烷基,具有6-20个碳原子的不饱和烃基或具有6-20个碳原子的烷基被至少一个芳环中断; Z是-CH 2 - , - CH 2 CH 2 - , - NH-NH-, - O - , - NH-, -O-NH-,-CH 2 -NH-,-CH 2 -O-,-NH-O-,-NH-CH 2, -O - CH 2 - 和-CH-CH-; Y是-NH 2,-O-CH 2 -C 6 H 5,-CO-CO- O-CH 3,和-O-CH 3; 已发现这些化合物治疗由棒状杆菌,诺卡氏菌,罗红球菌和分枝杆菌引起的基于微生物的感染。 这些化合物可用于治疗分枝杆菌细胞,例如结核分枝杆菌,耐药性结核分枝杆菌,胞内分枝杆菌,麻疯病,副结核分枝杆菌和致病性分枝杆菌属。
    • 2. 发明授权
    • Antimicrobial compounds
    • 抗菌化合物
    • US06713654B1
    • 2004-03-30
    • US09486550
    • 2000-08-28
    • Craig A. TownsendJames D. DickGary R. PasternackFrancis P. KuhajdaNicole M. Parrish
    • Craig A. TownsendJames D. DickGary R. PasternackFrancis P. KuhajdaNicole M. Parrish
    • C07C31500
    • C40B40/04C07C311/06C07C317/44
    • This invention provides methods for treating a mycobacterial infection by administering to an animal a pharmaceutical composition containing a compound having the formula R—SOn—Z—CO—Y, where R is an alkyl group having 6-20 carbons; Z is a radical selected from —CH2—, —O—, and —NH—, two of these radicals coupled together, or —CH2═CH2—; Y is —NH2, O—CH2—C6H5, —CO—CO—O—CH3, or O—CH3; and n is 1 or 2. It has been discovered that these compounds inhibit growth of microbial cells which synthesize &agr;-substitued, &bgr;-hydroxy fatty acids, particularly corynemycolic acid, nocardic acid, and mycolic acid. These compounds may be used to inhibit growth of mycobacterial cells, such as Mycobacterium tuberculosis, drug-resistant M. tuberculosis, M. avium intracellulare, and M. leprae.
    • 本发明提供了通过向动物施用含有具有式R-SOn-Z-CO-Y的化合物的药物组合物来治疗分枝杆菌感染的方法,其中R是具有6-20个碳原子的烷基; Z是选自-CH 2 - , - O-和-NH-的基团,这些基团中的两个连接在一起,或-CH 2 = CH 2 - ; Y是-NH 2,O-CH 2 -C 6 H 5,-CO-CO-O-CH 3或O-CH 3; 已经发现,这些化合物抑制合成α-取代的β-羟基脂肪酸,特别是氯霉素酸,诺卡酸和霉菌酸的微生物细胞的生长。 这些化合物可用于抑制分枝杆菌细胞的生长,例如结核分枝杆菌,耐药性结核分枝杆菌,胞内分枝杆菌和麻疯病。
    • 3. 发明授权
    • Inhibition of fatty acid synthase as a means to reduce adipocyte mass
    • 抑制脂肪酸合酶作为减少脂肪细胞质量的手段
    • US5981575A
    • 1999-11-09
    • US157
    • 1998-01-27
    • Francis P. KuhajdaGary R. PasternackCraig A. TownsendNeelakandha S. Mani
    • Francis P. KuhajdaGary R. PasternackCraig A. TownsendNeelakandha S. Mani
    • A61K31/00A61K31/365A61K31/381A61K31/4025A01K31/04
    • A61K31/4025A61K31/00A61K31/365A61K31/381
    • Weight loss was noted in nude mice treated with cerulenin, a non-competitive inhibitor of FAS. Sustained reduction of adipocyte mass in humans without toxicity would significantly impact disease prevention worldwide. Aside from psychological and self-esteem improvement, weight loss via reduction of adipocyte mass may: (1) ameliorate hyperglycemia associated with non-insulin-dependent diabetes mellitus thereby reducing diabetic complications such as arterial disease, blindness, cataracts, etc., (2) reduce hypertension, (3) reduce risk of coronary artery vascular disease and stroke, and (4) reduce the risk of other complications of massive obesity such as osteoarthritis, surgical complications, etc. There is also potential use in livestock and poultry to reduce the saturated fat content of meat products. Therefore FAS inhibitors are disclosed herein as novel agents for weight reduction. A family of compounds (.gamma.-substituted-.alpha.-methylene-.beta.-carboxy-.gamma.-butyrolactones) whose synthesis was based on the cerulenin motif is shown herein to inhibit fatty acid synthesis, inhibit growth in certain susceptible tumor cells, and induce weight loss.
    • PCT No.PCT / US96 / 17678 Sec。 371日期:1998年1月27日 102(e)日期1998年1月27日PCT 1996年11月15日PCT PCT。 第WO97 / 18806号公报 日期1997年5月29日在使用非竞争性FAS抑制剂的木瓜素治疗的裸小鼠中观察到重度损失。 持续减少人体脂肪细胞质量无毒性将严重影响全球疾病预防。 除了心理和自尊心的改善之外,通过减少脂肪细胞质量可以减轻体重:(1)改善与非胰岛素依赖性糖尿病相关的高血糖,从而减少糖尿病并发症,如动脉疾病,失明,白内障等(2 )降低高血压,(3)降低冠状动脉血管疾病和中风的风险,(4)降低骨质疏松,手术并发症等巨大肥胖的其他并发症的风险。畜禽养殖也有可能减少 肉制品的饱和脂肪含量。 因此,本文公开了FAS抑制剂作为减轻体重的新型药剂。 本文显示了其合成基于苏氨酸基序的化合物(γ-取代-α-亚甲基-β-羧基-γ-丁内酯)家族,以抑制脂肪酸合成,抑制某些易感的肿瘤细胞中的生长,并诱导体重减轻 。